Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Janux Therapeutics Inc (NQ: JANX )

10.73 +0.15 (+1.42%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 19, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 198,586
Open 10.50
Bid (Size) 10.73 (10)
Ask (Size) 65.00 (1)
Prev. Close 10.58
Today's Range 10.30 - 11.38
52wk Range 9.390 - 37.99
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Janux Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights
From Janux Therapeutics, Inc.
Via Business Wire
Janux Therapeutics to Present Preclinical Data at the 18th Annual PEGS Boston for PSMA-TRACTr and EGFR-TRACTr
From Janux Therapeutics
Via Business Wire

Performance

YTD
-46.99%
-46.99%
1 Month
-24.06%
-24.06%
3 Month
-34.01%
-34.01%
6 Month
-43.56%
-43.56%
1 Year
-57.34%
-57.34%

More News

Read More
Janux Therapeutics's Return On Capital Employed Overview
Via Benzinga
Janux Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results
From Janux Therapeutics, Inc.
Via Business Wire
Janux Therapeutics to Present Virtually at the H.C. Wainwright BioConnect Conference
From Janux Therapeutics, Inc.
Via Business Wire
Janux Therapeutics Reports Business Highlights and Third Quarter 2021 Financial Results
From Janux Therapeutics, Inc.
Via Business Wire
Janux Therapeutics to Present Virtually at Upcoming Investor Conferences
From Janux Therapeutics, Inc.
Via Business Wire
50 Biggest Movers From Yesterday
Via Benzinga
48 Biggest Movers From Friday
Via Benzinga
Janux Therapeutics Appoints Ron Barrett, Ph.D., and Alana McNulty to Board of Directors
From Janux Therapeutics, Inc.
Via Business Wire
Janux Therapeutics to Present Virtually at the H.C. Wainwright 23rd Annual Global Investor Conference
From Janux Therapeutics, Inc.
Via Business Wire
Janux Therapeutics Appoints Shahram Salek-Ardakani, Ph.D., Chief Scientific Officer
From Janux Therapeutics
Via Business Wire
84 Biggest Movers From Friday
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 6, 2021
Via Benzinga
The Week Ahead In Biotech: Focus On Chemocentryx FDA Decision, Conference Presentations In A Light Week
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: Regeneron COVID-19 Antibody Cocktail Data, FDA Nod For Mallinckrodt, Molecular Partners IPO
Via Benzinga
Exposures COVID-19 Product Safety
Janux Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Janux Therapeutics, Inc.
Via Business Wire
The Daily Biotech Pulse: AstraZeneca, Biogen Face Clinical Trial Disappointments, Novavax Studies Coronavirus-Flu Combo Vaccine, Decision Day For Takeda
Via Benzinga
60 Biggest Movers From Yesterday
Via Benzinga
Opening Day: Monday.com, Marqeta Jump In Market Debuts
Via Talk Markets
64 Biggest Movers From Friday
Via Benzinga
Topics Initial Public Offering
Exposures Securities Market
Mid-Afternoon Market Update: Crude Oil Rises 1%; Janux Therapeutics Shares Jump
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
46 Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Topics Initial Public Offering
Exposures Securities Market
Mid-Day Market Update: Markets Mixed; Novan Shares Spike Higher
Via Benzinga
Topics Stocks
Exposures US Equities
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.